Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q2

3151.TEDINET S100PL90
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥289.4bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥577.2bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥285.2bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥730m2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥934m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥2.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.4bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥2.4bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥2.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.5bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥1.5bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥316.4bnat 2022-09-30Cons.Assets
Total assets¥313.0bnat 2022-03-31Cons.Assets
Total assets¥327.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥212.8bnat 2022-09-30Cons.Liabilities
Total liabilities¥213.0bnat 2022-03-31Cons.Liabilities
Net assets / equity¥103.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥100.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥105.6bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥27.4bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥27.0bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥23.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.2bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥27.4bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.3bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥4.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥7.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥8.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥27.422022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.42022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.882021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥25.672021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.012021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio32.4%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.0%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥146m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥58m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-09-30¥278.2bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-09-30¥273.0bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-09-30¥607m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥32m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥178m
—segment totalrevenue2022-04-01 → 2022-09-30¥292.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥287.4bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥819m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥295.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥289.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥672m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥3.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30−¥97m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥5.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥5.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥19m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2021-04-01 → 2021-09-30¥273.4bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2021-04-01 → 2021-09-30¥269.1bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥4.3bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2021-04-01 → 2021-09-30¥739m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥83m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥189m
—segment totalrevenue2021-04-01 → 2021-09-30¥287.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥283.3bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥4.3bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥290.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥285.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥915m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 549
ItemContextValueUnit
Non operating incomePrior1YTDDuration1533000000JPY
Non operating incomeCurrentYTDDuration1794000000JPY
Interest expenses noePrior1YTDDuration48000000JPY
Interest expenses noeCurrentYTDDuration51000000JPY
Rent expenses noePrior1YTDDuration43000000JPY
Rent expenses noeCurrentYTDDuration41000000JPY
Other noePrior1YTDDuration20000000JPY
Other noeCurrentYTDDuration9000000JPY
Non operating expensesPrior1YTDDuration112000000JPY
Non operating expensesCurrentYTDDuration102000000JPY
Ordinary incomePrior1YTDDuration2355000000JPY
Ordinary incomeCurrentYTDDuration2423000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration11000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration13000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration59000000JPY
Other eiPrior1YTDDuration0JPY
Other eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration11000000JPY
Extraordinary incomeCurrentYTDDuration72000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration19000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration0JPY
Impairment loss elPrior1YTDDuration47000000JPY
Impairment loss elCurrentYTDDuration22000000JPY
Loss on valuation of investment securities elPrior1YTDDuration8000000JPY
Loss on valuation of investment securities elCurrentYTDDuration55000000JPY
Soil removal expenses elPrior1YTDDuration－JPY
Soil removal expenses elCurrentYTDDuration62000000JPY
Other elPrior1YTDDuration11000000JPY
Other elCurrentYTDDuration5000000JPY
Extraordinary lossPrior1YTDDuration87000000JPY
Extraordinary lossCurrentYTDDuration145000000JPY
Income before income taxesPrior1YTDDuration2280000000JPY
Income before income taxesCurrentYTDDuration2350000000JPY
Income taxesPrior1YTDDuration814000000JPY
Income taxesCurrentYTDDuration862000000JPY
Profit lossPrior1YTDDuration1466000000JPY
Profit lossCurrentYTDDuration1487000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration55000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration49000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration1411000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1437000000JPY
Profit lossPrior1YTDDuration1466000000JPY
Profit lossCurrentYTDDuration1487000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration1051000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration3806000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-194000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-178000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration61000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration213000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass